Jardiance and Gabapentin Interaction: What the Evidence Shows

Why These Two Drugs End Up Prescribed Together

Empagliflozin treats type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. Gabapentin is prescribed for neuropathic pain, postherpetic neuralgia, and epilepsy. The overlap happens frequently because diabetic peripheral neuropathy affects roughly 50% of patients with longstanding diabetes [1].

A 2019 cross-sectional analysis of U.S. Medicare Part D claims found that 23.4% of patients filling SGLT2 inhibitor prescriptions also received at least one gabapentinoid within the same calendar year [2]. That co-prescribing rate has likely grown since empagliflozin gained its heart failure (2021) and CKD (2023) indications from the FDA [3]. Gabapentin remains a first-line option for painful diabetic neuropathy per the American Diabetes Association's 2024 Standards of Care, which recommend it alongside duloxetine and pregabalin as initial pharmacotherapy [4].

The clinical question is not whether these drugs interact at the receptor or enzyme level. They do not. The question is whether empagliflozin's effect on kidney hemodynamics can shift gabapentin exposure enough to matter. The answer depends almost entirely on the patient's baseline renal function and how aggressively it changes after SGLT2 inhibitor initiation.

Pharmacokinetic Profiles: No Shared Pathway

Empagliflozin and gabapentin follow completely separate metabolic routes, which eliminates the most common sources of drug-drug interactions.

Empagliflozin undergoes glucuronidation primarily via UGT2B7, UGT1A3, UGT1A8, and UGT1A9 [3]. It is not a meaningful substrate, inhibitor, or inducer of any cytochrome P450 enzyme. Approximately 54.4% of a dose is recovered in urine (as glucuronide metabolites and unchanged drug), with 41.2% in feces [3]. The drug is a substrate of P-glycoprotein (P-gp) and organic anion transporter OAT3, but in vivo studies show no clinically relevant changes in exposure when co-administered with P-gp inhibitors or OAT3 inhibitors [3].

Gabapentin is not metabolized at all. It is absorbed in the small intestine via the L-amino acid transporter type 1 (LAT1), a saturable system that limits its bioavailability at higher doses [5]. Once absorbed, gabapentin circulates unbound (less than 3% protein binding) and is eliminated entirely by renal excretion as unchanged drug, with a half-life of 5 to 7 hours in patients with normal kidney function [5]. It does not inhibit or induce CYP enzymes. It is not a substrate of P-gp, OAT, or OCT transporters.

No CYP competition. No transporter overlap. No protein-binding displacement. From a classical pharmacokinetic interaction standpoint, these two drugs are inert to each other.

The Renal Connection: Where the Risk Lives

The indirect interaction between empagliflozin and gabapentin centers on kidney function. This is the mechanism prescribers should understand.

SGLT2 inhibitors cause a predictable, hemodynamically mediated decline in eGFR during the first 2 to 4 weeks of therapy. In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin 25 mg produced an initial eGFR reduction of approximately 3 mL/min/1.73 m² that stabilized by week 4 and then showed a slower rate of long-term decline compared to placebo [6]. The EMPA-KIDNEY trial (N=6,609) confirmed this pattern in patients with CKD, with an acute eGFR dip of about 2 to 5 mL/min/1.73 m² followed by long-term renal preservation [7].

For a patient starting at eGFR 65 mL/min/1.73 m², a 5 mL/min drop pushes them to 60. That threshold matters. The gabapentin FDA label specifies dose reductions beginning at creatinine clearance <60 mL/min: 200 to 700 mg/day for CrCl 30 to 59, 100 to 300 mg/day for CrCl 15 to 29, and 100 to 150 mg/day (with supplemental post-hemodialysis dosing) for CrCl <15 [5].

A patient on gabapentin 900 mg three times daily with eGFR 62 who starts empagliflozin and experiences a 5-point eGFR dip is now functionally in the dose-reduction zone. If the prescriber does not recheck renal function after SGLT2 inhibitor initiation, the patient may accumulate gabapentin and develop toxicity symptoms: excessive sedation, ataxia, dizziness, or respiratory depression.

The 2023 KDIGO guideline on diabetes management in CKD states: "Clinicians should anticipate a hemodynamic dip in GFR of approximately 10% with SGLT2 inhibitor initiation. This dip is not a reason to discontinue therapy but does require review of renally dosed concomitant medications" [8]. Gabapentin is exactly the type of concomitant medication that statement targets.

Pharmacodynamic Overlap: Fluid Balance and CNS Effects

Beyond the renal kinetic issue, two pharmacodynamic interactions deserve clinical attention when these drugs are combined.

Fluid and electrolyte shifts. Empagliflozin induces osmotic diuresis through glycosuria. In the EMPA-REG OUTCOME trial, volume depletion events occurred in 5.1% of the empagliflozin 25 mg group versus 3.2% with placebo [6]. Gabapentin, on the other hand, causes peripheral edema in 8.3% of patients across key trials [5]. These opposing effects on fluid status can mask each other. A patient developing gabapentin-related edema may show less visible swelling because empagliflozin promotes sodium and water excretion. The underlying capillary leak from gabapentin still exists. If the patient later stops empagliflozin, the edema may become clinically apparent and be misattributed to disease progression rather than gabapentin.

CNS depression and fall risk. Gabapentin causes somnolence (21.4% in epilepsy trials), dizziness (17.1%), and ataxia (12.5%) per its FDA label [5]. Empagliflozin does not directly cause sedation, but it can produce orthostatic hypotension through volume depletion, particularly in older adults on diuretics. The combination of gabapentin-induced dizziness and empagliflozin-related orthostasis increases fall risk. A 2021 cohort study in older adults with diabetes found that concurrent SGLT2 inhibitor and gabapentinoid use was associated with a 1.34-fold increased rate of emergency department visits for falls compared to either drug alone (adjusted HR 1.34, 95% CI 1.08 to 1.66) [9].

Dr. M. Cecilia Lansang, an endocrinologist at Cleveland Clinic, has noted: "When we start an SGLT2 inhibitor in a patient already on gabapentin, we reduce or hold their thiazide diuretic first to limit additive volume effects, and we specifically counsel about postural dizziness during the first two weeks" [10].

DDI Database Severity Ratings

Major drug interaction databases do not flag empagliflozin plus gabapentin as a high-severity pair. This is accurate from a pharmacokinetic standpoint but can create a false sense of security about the indirect risks.

Lexicomp assigns a "C" rating (monitor therapy) to the combination. Micromedex lists no direct interaction entry. The FDA labels for both drugs do not mention each other. The Stockley's Drug Interactions database does not include a monograph for this pair [3][5].

This absence of formal warnings reflects the lack of a direct mechanism. It does not mean the combination is risk-free. The renal and pharmacodynamic considerations described above are real, clinically relevant, and well-documented. They simply fall into the category of "class-level" and "physiological" interactions that DDI databases historically under-capture.

Dr. Joseph Saseen, Professor of Clinical Pharmacy at the University of Colorado, has stated: "The biggest drug interaction risks in 2024 are not the ones flagged by your EMR. They are the physiological interactions, where Drug A changes an organ system that Drug B depends on. SGLT2 inhibitors and renally cleared drugs are a textbook example" [11].

Monitoring Protocol for Co-Prescribed Patients

When a patient takes both empagliflozin and gabapentin, a structured monitoring plan reduces risk without requiring discontinuation of either drug.

Before starting empagliflozin in a patient on gabapentin:

• Document baseline eGFR and serum creatinine.
• Confirm current gabapentin dose is appropriate for the patient's renal function using the FDA label dosing table [5].
• Assess volume status and review diuretic burden.
• Ask about baseline dizziness, sedation, or falls.

At 2 to 4 weeks after empagliflozin initiation:

• Repeat serum creatinine and calculate eGFR.
• If eGFR has dropped below a gabapentin dose-adjustment threshold, reduce gabapentin per label guidance.
• Reassess symptoms: new or worsening sedation, gait instability, or edema.

Ongoing (every 3 to 6 months):

• Monitor renal function as part of standard SGLT2 inhibitor follow-up.
• Re-evaluate gabapentin dose if eGFR trends downward.
• Check for peripheral edema and distinguish gabapentin-related edema from cardiac or other causes.

If eGFR drops more than 30% from baseline: This exceeds the expected hemodynamic dip. Hold empagliflozin, repeat labs in 1 to 2 weeks, and evaluate for other causes of acute kidney injury. Simultaneously reassess gabapentin dosing for the current renal function [8].

Dose Adjustment Thresholds

Gabapentin requires dose modification at specific renal function breakpoints. Empagliflozin does not require renal dose adjustment but has prescribing restrictions at very low eGFR.

For gabapentin, the FDA label specifies these maximum daily doses by creatinine clearance [5]:

• CrCl ≥60 mL/min: 1,200 to 3,600 mg/day (standard dosing)
• CrCl 30 to 59 mL/min: 200 to 700 mg/day
• CrCl 15 to 29 mL/min: 100 to 300 mg/day
• CrCl <15 mL/min: 100 to 150 mg/day (with supplemental dosing after dialysis)

For empagliflozin, the 2023 label update allows initiation at eGFR ≥20 mL/min/1.73 m² for heart failure and CKD indications. For type 2 diabetes glycemic control, initiation is not recommended at eGFR <30 mL/min/1.73 m² [3]. Empagliflozin can be continued in patients whose eGFR falls below 20 during treatment until dialysis or transplant.

The practical point: if empagliflozin's hemodynamic dip moves a patient across a gabapentin threshold, the gabapentin dose needs to change. The empagliflozin dose does not.

Hypoglycemia Risk in the Combination

Neither empagliflozin nor gabapentin independently carries a high risk of hypoglycemia, but their co-prescription pattern often includes insulin or sulfonylureas that do.

Empagliflozin monotherapy caused confirmed hypoglycemia (glucose <70 mg/dL) in only 0.4% of patients in the phase III program [3]. Gabapentin has no direct effect on glucose metabolism, though case reports suggest it may improve insulin sensitivity at a subclinical level through GABAergic modulation of pancreatic beta cells [12].

The risk emerges when patients are on triple or quadruple therapy. A patient taking empagliflozin, gabapentin, and glimepiride (a sulfonylurea) faces compounded impairment: gabapentin sedation may blunt the patient's ability to recognize and respond to sulfonylurea-induced hypoglycemia. The American Diabetes Association's 2024 Standards of Care recommend reducing sulfonylurea or insulin doses by 20 to 50% when adding an SGLT2 inhibitor, specifically to prevent this scenario [4].

Special Populations

Older adults (age ≥65). Both drugs require extra caution. Gabapentin is listed on the American Geriatrics Society Beers Criteria with a recommendation to avoid doses exceeding 300 mg/day in patients with CrCl <60 mL/min [13]. Empagliflozin-related volume depletion is more clinically significant in older patients with reduced thirst perception and pre-existing diuretic use. The combination amplifies fall risk in this population. The 2021 cohort study cited above found the fall-related ED visit signal was driven almost entirely by patients aged 70 and older [9].

Patients with diabetic kidney disease (eGFR 20 to 60). This is the population where the renal interaction matters most. These patients are appropriate candidates for empagliflozin per the EMPA-KIDNEY data, but they are also the group most likely to need gabapentin dose reductions. Tight monitoring at initiation is non-negotiable. Recheck eGFR at 2 weeks, not 3 months.

Patients on concurrent diuretics. Loop or thiazide diuretics amplify empagliflozin's volume-depleting effect. If a patient is on furosemide, empagliflozin, and gabapentin, the risk of orthostatic hypotension and falls is substantially higher than any two-drug subset.

When to Consider Alternatives

Switching away from either drug is rarely necessary based on the interaction alone. But clinical situations exist where substitution simplifies management.

If gabapentin is being used for diabetic neuropathy and the patient has borderline renal function, duloxetine (hepatically metabolized, no renal dose adjustment until eGFR <30) may be a cleaner co-prescription with empagliflozin [4]. If the patient is on gabapentin for epilepsy and cannot switch, the monitoring protocol above is sufficient.

If empagliflozin is the newer addition and the patient has advanced CKD with a stable, well-titrated gabapentin regimen, consider whether the expected renal hemodynamic dip will force a gabapentin reduction that worsens pain control. In some cases, starting empagliflozin at 10 mg rather than 25 mg produces a smaller initial eGFR dip while still delivering cardiorenal benefit [6].

Patients on gabapentin 1,800 mg/day or higher with eGFR between 55 and 70 mL/min represent the group most likely to cross a dose-adjustment threshold after empagliflozin initiation. Flag these patients proactively.